State Street Corp. Updates Passive Stake in Emergent BioSolutions
Ticker: EBS · Form: SC 13G/A · Filed: Jan 23, 2024 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | SC 13G/A |
| Filed Date | Jan 23, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, amendment, passive-investment
TL;DR
**State Street Corp. still holds Emergent BioSolutions stock, showing continued institutional confidence.**
AI Summary
State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 23, 2024, indicating its ownership of Emergent BioSolutions Inc. common stock as of December 31, 2023. This filing is an update to their previous disclosures, confirming their continued passive investment in the pharmaceutical company. For investors, this means a significant institutional holder maintains its position, which can be a signal of confidence, though the exact percentage of ownership is not detailed in this excerpt.
Why It Matters
This filing confirms State Street Corporation's ongoing passive investment in Emergent BioSolutions, signaling continued institutional interest in the company's stock.
Risk Assessment
Risk Level: low — This is a routine update from a large institutional investor, indicating a passive stake, which generally poses low risk.
Analyst Insight
Investors should note that a major institutional investor like State Street Corporation continues to hold a position in Emergent BioSolutions, which could be interpreted as a baseline level of confidence in the company, but this filing alone doesn't suggest any immediate catalysts or changes in strategy.
Key Numbers
- 29089Q105 — CUSIP Number (Identifies Emergent BioSolutions Inc. common stock)
- 12/31/2023 — Date of Event (The date as of which State Street Corporation's ownership is being reported)
Key Players & Entities
- State Street Corporation (company) — the reporting person and institutional investor
- Emergent BioSolutions Inc. (company) — the subject company whose common stock is being reported
- 0000093751-24-000103 (dollar_amount) — accession number for the filing
- 20240123 (date) — filing date
- 12/31/2023 (date) — date of event requiring the filing
- 29089Q105 (other) — CUSIP number for Emergent BioSolutions Inc. common stock
Forward-Looking Statements
- State Street Corporation will maintain a passive investment strategy in Emergent BioSolutions Inc. for the foreseeable future. (State Street Corporation) — high confidence, target: Q4 2024
FAQ
What is the purpose of this specific SC 13G/A filing?
This SC 13G/A filing, dated January 23, 2024, is an amendment by State Street Corporation to update its previous disclosures regarding its passive ownership of common stock in Emergent BioSolutions Inc. as of December 31, 2023, under Rule 13D-1(B).
Who is the reporting person in this filing?
The reporting person is State Street Corporation, with an I.R.S. Identification No. of 04-2456637, as stated on Page 2 of 5 of the filing.
What is the subject company whose securities are being reported?
The subject company is Emergent BioSolutions Inc., identified by the CUSIP number 29089Q105, as stated on the cover page of the filing.
What type of securities are covered by this filing?
This filing covers 'COMMON STOCK' of Emergent BioSolutions Inc., as indicated on the cover page of the Schedule 13G.
What was the date of the event that triggered this filing?
The date of the event which required the filing of this statement was December 31, 2023, as specified on the cover page of the Schedule 13G.
Filing Details
This Form SC 13G/A (Form SC 13G/A) was filed with the SEC on January 23, 2024 regarding Emergent BioSolutions Inc. (EBS).